TNYA on Nasdaq

Tenaya Therapeutics, Inc.

American biological products company, incorporated in Delaware.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

  • TickerTNYA on Nasdaq
  • IndustryBiological Products, (No Diagnostic Substances)
  • HeadquartersDE
  • Incorporated inDE2
  • Business address171 Oyster Point Blvd., Suite 500, South San Francisco, Ca 940802
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income34567-$93.3M in 2025+140% since 2020
-$150.0M-$100.0M-$50.0M02020: -$38.9M-$38.9M20202021: -$72.8M-$72.8M2021+87%2022: -$125.6M-$125.6M2022+73%2023: -$131.2M-$131.2M2023+4%2024: -$115.9M-$115.9M2024−12%2025: -$93.3M-$93.3M2025−20%
Net income34567-$90.6M in 2025+136% since 2020
-$150.0M-$100.0M-$50.0M02020: -$38.4M-$38.4M20202021: -$72.7M-$72.7M2021+89%2022: -$123.7M-$123.7M2022+70%2023: -$124.1M-$124.1M2023+0%2024: -$111.1M-$111.1M2024−10%2025: -$90.6M-$90.6M2025−18%

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
Research and development$68.6M$86.7M
General and administrative$24.7M$29.2M
Total operating expenses$93.3M$115.9M
Loss from operations-$93.3M-$115.9M
Interest income$2.7M$4.7M
Other income, net$52.0K$82.0K
Total other income, net$2.7M$4.8M
Net loss before income tax expense-$90.6M-$111.1M
Net loss-$90.6M-$111.1M
Net unrealized (loss) gain on marketable securities-$28.0K$134.0K
Comprehensive loss-$90.6M-$111.0M
Net loss per share, basic-$0.59-$1.31
Net loss per share, diluted-$0.59-$1.31
Weighted-average shares used in computing net loss per share, basic153.0M shares84.8M shares
Weighted-average shares used in computing net loss per share, diluted153.0M shares84.8M shares

Compare Tenaya Therapeutics, Inc. with another company

Leadership

Who has led Tenaya Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Faraz Ali2021–now

Chief financial officer

  1. Eric J. Hyllengren2026–now
2025
Board members and other officers (17)

Timeline

  1. Jul 29, 2021New chief executive Faraz Ali becomes CEO10

Filings

302 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 51 major events, 125 insider forms, 37 large holders, 69 other. The latest 20:

  1. Oct 13, 2026PRE 14A EDGAR
  2. Sep 11, 20264 EDGAR
  3. Sep 11, 20264 EDGAR
  4. Aug 24, 2026SCHEDULE 13G EDGAR
  5. Aug 17, 20264 EDGAR
  6. Aug 17, 20264 EDGAR
  7. Aug 17, 2026144 EDGAR
  8. Aug 17, 2026144 EDGAR
  9. Aug 5, 2026S-8 EDGAR
  10. Aug 5, 202610-Q EDGAR
  11. Aug 5, 20268-K EDGAR
  12. Jul 14, 20263 EDGAR
  13. Jul 14, 20264 EDGAR
  14. Jul 2, 20268-K EDGAR
  15. Jun 29, 20268-K EDGAR
  16. May 29, 20264 EDGAR
  17. May 29, 20264 EDGAR
  18. May 29, 20264 EDGAR
  19. May 29, 20264 EDGAR
  20. May 29, 20264 EDGAR

The 302 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 37 such filings since October 2021, the latest 10:

  1. Aug 24, 2026SCHEDULE 13G
  2. Feb 26, 2026SCHEDULE 13D/A
  3. Feb 12, 2026SCHEDULE 13D/A
  4. Dec 17, 2025SCHEDULE 13D/A
  5. Aug 14, 2025SCHEDULE 13G/A
  6. Jul 31, 2025SCHEDULE 13G/A
  7. May 15, 2025SCHEDULE 13G
  8. May 14, 2025SCHEDULE 13D/A
  9. May 7, 2025SCHEDULE 13G
  10. Mar 7, 2025SCHEDULE 13D/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC7,101,263$5.2M0.0%−1,381,025
Millennium Management LLC6,429,648$4.8M0.0%+972,982
Citadel Advisors LLC4,566,774$3.4M0.0%+366,774
Renaissance Technologies LLC4,281,100$3.2M0.0%+567,339
BlackRock, Inc.4,008,719$3.0M0.0%+304,764
Empery Asset Management, LP3,863,115$2.9M3.3%−423,818
Marshall Wace, Llp3,503,178$2.6M0.0%+797,788
Burkehill Global Management, LP2,000,000$1.5M0.1%No change
Geode Capital Management, LLC1,834,674$1.4M0.0%+274,735
ADAR1 Capital Management, LLC1,555,500$1.1M0.1%+47,700
Raiffeisen Bank International AG1,200,000$881.9K0.0%+200,000
Euclidean Capital LLC1,015,705$750.7K0.2%No change
Vanguard Fiduciary Trust Co987,505$729.8K0.0%−28,197
Mirador Capital Partners LP905,097$669.0K0.1%+18,180
State Street Corp708,721$523.8K0.0%No change
Squarepoint Ops LLC659,247$487.2K0.0%+310,979
StepStone Group LP462,163$341.5K0.0%No change
UBS Group AG456,555$337.4K0.0%−208,625
Jane Street Group, LLC450,435$332.9K0.0%−729,646
Two Sigma Investments, LP380,790$281.4K0.0%−899,600
Casdin Capital, LLC361,969$267.5K0.0%No change
Invesco Ltd.354,862$262.3K0.0%+216,856
Northern Trust Corp346,371$256.0K0.0%+35,717
Susquehanna International Group, Llp325,316$240.4K0.0%+16,544
XTX Topco Ltd313,488$231.7K0.0%+284,286

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27